GlassScriptPhysician profile
John W Hannah
NPI 1295849982
$4,569.09
in general payments reported to CMS, 2019-2025
30 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $229 · 2021: $484 · 2022: $597 · 2023: $689 · 2024: $1,650 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Travel and Lodging: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.19 |
| Travel and Lodging | $973.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,435.78 | 2023-2024 | Urolift |
| Astellas Pharma US INC | $625.84 | 2019-2025 | Myrbetriq, Xtandi, Padcev |
| Endo Pharmaceuticals INC. | $559.00 | 2019-2024 | Xiaflex |
| Endo USA, INC. | $272.60 | 2024-2025 | Xiaflex |
| Pfizer INC. | $231.72 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $187.61 | 2023 | Gemtesa |
| Axonics, INC. | $176.21 | 2021-2023 | Axonics, Bulkamid |
| Boston Scientific Corporation | $151.65 | 2019-2025 | Rezum Generator, Polaris Ultra |
| Urovant Sciences INC | $147.58 | 2021-2022 | |
| Dornier Medtech America, INC | $145.62 | 2022 | |
| Blue Earth Diagnostics | $91.14 | 2019-2022 | |
| Neotract INC. | $76.45 | 2019 | |
| Abbvie INC. | $75.84 | 2019-2024 | |
| Antares Pharma, INC. | $45.66 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.50 | 2024 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $32.44 | 2025 | Itind System |
| Allergan, INC. | $31.78 | 2019-2022 | |
| Myovant Sciences INC. | $30.13 | 2021 | |
| Alnylam Pharmaceuticals INC. | $29.86 | 2024 | Givlaari |
| 180 Medical, INC. | $25.77 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $23.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.75 | 2023 | |
| Ambu INC. | $21.28 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $19.40 | 2024 | |
| Merck Sharp & Dohme LLC | $15.71 | 2023 | Lynparza, Welireg, Keytruda |
| Aytu Biopharma, INC. | $14.98 | 2019 | |
| Coloplast Corp | $14.53 | 2025 | |
| Medtronic, INC. | $14.27 | 2025 | Emprint |
| Sagent Pharmaceuticals | $11.07 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$408.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hannah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.